Navigation Links
Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy

BELMONT, Calif., April 4, 2011 /PRNewswire/ -- Ventus Medical, Inc. today reported positive results from a 19 center clinical trial using its FDA-cleared Provent® Sleep Apnea Therapy device to treat obstructive sleep apnea. Provent Therapy uses the patient's own breathing to create expiratory positive airway pressure (EPAP) to keep the airway open during sleep. The full results of this three month study were published in the April 2011 issue of the peer-reviewed medical journal SLEEP, an official publication of the American Academy of Sleep Medicine.



"This randomized, sham-controlled study demonstrates that Provent Therapy significantly improves the apnea hypopnea index (AHI), a scale to measure the number of breathing interruptions or stoppages per hour of sleep, as well as subjective sleepiness, as measured by the Epworth Sleepiness Scale (ESS) in patients with obstructive sleep apnea," said study author Richard B. Berry, M.D., professor of medicine at the University of Florida College of Medicine, medical director of the University of Florida and Shands Sleep Disorders Center, and former president of the American Sleep Medicine Foundation. "Importantly, self-reported patient adherence on Provent Therapy was almost 90 percent."

The prospective, double-blind, sham-controlled clinical study enrolled 250 patients diagnosed with obstructive sleep apnea at 19 academic and private sleep centers in the United States.  The primary endpoint of the study was the reduction in AHI.  In-laboratory polysomnography, a method of monitoring breathing disruptions during sleep, was performed at the start of the study and after three months of treatment.

Results at the start of the study showed that AHI was reduced by 52.7 percent in the Provent Therapy group compared to a 7.3 percent reduction in the sham group, representing a highly significant treatment effect (p<0.0001). A highly significant improvement in AHI was also demonstrated at the conclusion of the study. Using the Epworth Sleepiness Scale to evaluate daytime sleepiness, patients using Provent Therapy showed improved alertness, reducing sleepiness from 9.9 +/- 4.7 to 7.2 +/- 4.2 compared to the sham group of 9.6 +/- 8.3 to 8.3 +/- 5.1 , a statistically significant improvement compared to the sham group (p=0.04). Importantly, self-reported patient adherence was excellent, with the Provent Therapy device worn all night for 88.2 percent of nights in the study.

"CPAP is the gold standard in the treatment for obstructive sleep apnea, but unfortunately many patients who are prescribed CPAP cannot get used to it, or use it less often than they should," stated study author Meir Kryger, M.D., director of sleep medicine research and education at Gaylord Hospital in Wallingford, Connecticut and former president of the American Academy of Sleep Medicine. "This large trial provides solid clinical data validating Provent Therapy as an important treatment alternative for obstructive sleep apnea."  

About Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is the most common type of sleep-disordered breathing. It is estimated that 40 million people in the United States suffer from sleep apnea. In people with OSA, the airway collapses during sleep when the muscles, that hold the airway open, relax. People with this disorder can stop breathing while sleeping---in some cases hundreds of times each night---usually for periods of ten seconds or longer. Importantly, many recent studies have shown that people with OSA experience higher rates of car accidents as well as serious health problems including high blood pressure, heart attack, stroke and diabetes.

Unfortunately, OSA often goes undiagnosed and therefore untreated. Of the patients that do receive treatment, most are prescribed a CPAP machine. CPAP is extremely effective at treating OSA if worn as directed. However, more than half of all patients stop treatment with CPAP due to its cumbersome nature. Provent Therapy was developed to help patients who do not use CPAP regularly and who can benefit from a non-invasive and clinically effective treatment alternative.

About Provent Sleep Apnea Therapy

Provent Therapy is a prescription device indicated for the treatment of obstructive sleep apnea. It is an easy-to-use, disposable treatment that works across mild, moderate and severe OSA. Provent Therapy is cleared by the U.S. Food and Drug Administration (FDA) and numerous peer-reviewed published studies have demonstrated that Provent Therapy improves sleep apnea and oxygenation. The device works through Ventus Medical's proprietary MicroValve technology that uses the patient's own breathing to create expiratory positive airway pressure (EPAP) to keep the airway open during sleep. For more information, please visit

About Ventus Medical

Ventus Medical is a privately-held medical device company dedicated to providing non-invasive medical solutions for people with sleep-disordered breathing. Based on its innovative MicroValve technology and patented designs, Ventus Medical has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea to snoring. Ventus Medical devices work by creating expiratory positive airway pressure (EPAP). The company markets FDA-cleared, prescription-only Provent Therapy, a discreet, easy-to-use nasal device, for the treatment of obstructive sleep apnea and is developing an over-the-counter device for snoring.

SOURCE Ventus Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study
4. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
5. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
6. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
7. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
8. Industry Executives Finding Value in Shift of Scientific Publications
9. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
10. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
11. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
Post Your Comments:
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... Research and Markets ( ) has announced the addition ... 2019 - Rise in Cardiac Disorders and Growing Awareness among ... offering. Boston scientific and ... and others. --> The market is dominated ... scientific and others. Asia ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... The men and women on this ... in the country. They have overseen financial turnarounds, shown commitment to their community ... industry as a whole through their advocacy and professional efforts. , Becker's Hospital ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
Breaking Medicine News(10 mins):